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Abstract 
This project introduces two mathematical models representing the biochemical interactions 
between insulin signaling, PD, and AD. The models can be used to examine the changes that 
occur over the course of the disease as well as identify which processes would be the most 
effective targets for treatment. The models are mathematized using Biochemical Systems 
Theory. They incorporate treatment strategies that includes several experimental drugs along 
with current treatments. In the past, BST models of neurodegeneration have used Power Law 
Analysis and Simulation to model the system. This work recommends the use of MATLAB 
instead. MATLAB allows for more flexibility in both the model itself and in data analysis. 
Previous BST analyses of neurodegeneration began treatment at disease onset. As shown in these 
models, the outcomes of delayed, realistic treatment and full treatment at disease onset are 
significantly different. The delayed treatment strategy is an important development in BST 
modeling of neurodegeneration. It emphasizes the importance of early diagnosis, and allows for 
a more accurate representation of disease and treatment interactions. 
 
1. Introduction 
PD is a neurodegenerative disorder characterized by dopaminergic neuron death in the substantia 
nigra pars compacta and results in physical symptoms such as tremors, rigidity, and bradykinesia 
as well as psychological symptoms such as an increased risk of dementia, depression, and 
anxiety.  Insulin resistance, a precursor of T2DM, is a result of a diet high in fats and sugars. 
Insulin signaling pathways and PD pathogenesis have been experimentally proven to converge 
(Morris et al., 2008; Morris et al., 2011), yet clinical data is inconsistent (Bosco et al., 2012). The 
model includes production of ROS and RNS, p38 phosphorylation, tau protein 
hyperphosphorylation, inflammation, and dopamine synthesis, degradation, and transport. This 
paper presents a mathematical model that details the interactions between these processes and 
how they can combine to influence neuronal death. 
 
AD is an age-related neurodegenerative disorder affecting many brain regions, notably the 
cholinergic neurons in the hippocampus, which are correlated to the cognitive decline 
characteristic of AD (Kerbler et al., 2015). Insulin resistance in AD is much more accepted than 
in PD. Both a lack of insulin in the CNS, similar to T1DM, and a lack of CNS insulin receptor 
sensitivity, similar to T2DM, have been associated with AD, leading some to suggest that AD 
should be known as “type-III diabetes” (de la Monte et al., 2014). This paper presents a model of 
the pathways shared between insulin signaling impairment and AD within cholinergic neurons, 
astrocytes, and microglia. The data presented focuses on changes in insulin signaling, 
inflammation, ROS production, mitochondrial dysfunction, Ca2+ signaling dysregulation, 
neurofibrillary tangle production, Aβ oligomerization, p38 activation, and finally cell death. 
 
These disease simulations makes use of a modeling strategy know as BST, which was 
established  by Savageu  in 1969 and developed further by Voit in 2000. BST uses ODEs to 
model changes in reaction rates and species concentrations throughout the progression of the 
disease. These models include a baseline state, which depicts a healthy cell, a disease state, 
modeling a cell with PD and insulin resistance, and a treatment state, which is a disease state cell 
including several treatment options. The disease state was created by activating trigger points 
within the baseline model that initiated disease development, and the treatment state was created 
by introducing a mixture of drugs at two times: the onset of the disease, and halfway through the 
disease progression. These treatments target reactions the models show are important in 
neurodegenerative pathogenesis where it converges with insulin signaling pathways. 
 
2. Methods 
2.1 Modeled Pathways in PD 
This section explains several key pathways in the model, demonstrating the extent to which 
insulin signaling influences the biochemistry of PD. The system was modeled using the 
biochemical pathway visualization program CellDesigner.  
 
2.1.1 Insulin Signaling and Inflammation 
Insulin signaling begins with insulin binding to the insulin receptor on the cellular membrane, 
which causes phosphorylation of the insulin receptor substrate (Takahashi et al., 1996). Insulin 
signaling is promoted by PPARG, which is also a transcription factor for proteins important in 
antioxidant scavenging and mitochondrial repair (Miranda et al., 1999; Mudo et al., 2012; Xing 
et al., 2007). Insulin signaling is inhibited by the chronic inflammation present in PD. The 
inflammation is a result of cytokine production in astrocytes and microglia, specifically 
cytokines IL-1β, IL-6, TNFα, and MCSF (Ghosh et al., 2007; Glass et al., 2010). Overproduction 
of NO promoted by nitric oxide synthase (Hunot et al., 1996), prostaglandin synthesis promoted 
by COX2 (Xing et al., 2007), and NF-κB in the neuron and glia are also contributing factors. 
Inflammation is decreased by the presence of PPARG (Ricote et al., 1998). This process is 
outlined in Model 1. 
 2.1.2 Dopamine 
Dopamine is produced in the neuron through the conversion of tyrosine to L-DOPA, and L-
DOPA to dopamine (Model 2). Tyrosine hydroxylase, which is activated via phosphorylation by 
phosphorylated p38, promotes L-DOPA synthesis, and decarboxylase promotes the final step in 
the process to produce dopamine (Yu et al., 2005). Dopamine can also enter the cell through the 
dopamine transporter, which is upregulated by insulin signaling (Patterson et al., 1998). Free 
dopamine in the cell can be degraded into quinones, H2O2, and O2- (Yu et al., 2005), or use a 
Model 1: Mechanisms of inflammation and factors influencing insulin signaling in PD 
monoamine oxidase promoter, producing H2O2 and DOPAL (Marchitti et al., 2007). 
Alternatively, dopamine is collected into vesicles to be released at synapses. Vesicular dopamine 
is protected from degradation and the resulting production of ROS.  VMAT are important in 
sequestering the dopamine into vesicles. VMAT is downregulated in PD (Xiong et al., 2011).  
 
Model 2: Reactions and cellular processes involving dopamine in PD 
2.1.3 ROS and RNS 
ROS are the result of dopamine degradation and mitochondrial dysfunction in PD. Mitochondrial 
dysfunction creates an excess of O2-, which can be converted to H2O2 by SOD2. The H2O2 can 
then be converted to water by glutathione or catalase (Evans et al., 2002), or OH- by Fe through 
the Fenton reaction. Dopamine degradation also produces H2O2  and O2- in the cell. NO, a RNS, 
is produced in both the neuron and the glia from L-citrulline, and is membrane-permeable 
(Hunot et al., 1996). The NO can react with O2- to create ONOO-, which is extremely dangerous 
to the neuron (Beckman, Crow, 1993). Excessive ROS and RNS can react easily with vital 
cellular species causing lipid peroxidation, misfolded proteins, DNA damage, and endoplasmic 
reticulum and mitochondrial stress, all of which decrease cellular function and increase the risk 
of cell death. ROS and RNS can also trigger the caspase cascade, initiating apoptosis (Choi et al., 
2004; Ko et al., 2005).  
Model 3: Synthesis and degradation of reactive oxygen and nitrogen species in PD 
2.1.4 Tau Phosphorylation, Neurofibrillary Tangles, and Lewy Bodies 
Insulin signaling phosphorylates PI3K (Piao et al., 2012), which in turn phosphorylates PIP2, 
creating PIP3. PIP3 deactivates GSK-3β through phosphorylation, which prevents it from 
promoting tau hyperphosphorylation (Lucas et al., 2001). Tau hyperphosphorylation is also 
promoted by phosphorylated p38 (Zarubin, Han, 2005). The tau protein is important in 
microtubule stabilization, so the loss of function caused by the hyperphosphorylation results in 
impeded axonal transport. Hyperphosphorylated tau is a component of aggregates such as 
neurofibrillary tangles and Lewy bodies, which are characteristic of PD (Arima et al., 1999; 
Bancher et al., 1993). Lewy bodies also contain proteins such as parkin and α-synuclein, which 
aggregate as a result of ROS interactions that cause them to misfold (Winklhofer et al,  2003; 
Zheng et al., 2010).  
Model 4: The effects of insulin resistance on tau hyperphosphorylation, neurofibrillary tangle 
accumulation, and Lewy body production in PD 
 2.1.5 p38 Phosphorylation 
The p38 mitogen-activated protein kinase is involved in several different pathways in this model. 
p38 is activated by phosphorylation, which is promoted by prostaglandins, tumor necrosis factor 
α receptor 1 signaling, and ROS (Choi et al., 2004). Inhibition of p38 phosphorylation is caused 
by insulin signaling (Heidenreich, Kummer, 1996) and the MKP-1 expressed by the DUSP1 
gene (Taylor et al., 2013). p38 promotes caspase 9 maturation leading to apoptosis, tau 
phosphorylation, tyrosine hydroxylase activation, Bax/tBID complex formation resulting in 
mitochondrial membrane depolarization and related dysfunction, and finally Hsp27 activation 
Model 5: Mechanisms influencing p38 phosphorylation and its effects on the cell in PD 
(Snyder et al., 2009; Yu et al., 2005; Zarubin, Han, 2005). Hsp27 can inhibit tau 
phosphorylation, increase glutathione expression, inhibit Fas ligand binding, and decrease Lewy 
body formation by preventing α-synuclein aggregates from accumulating in the Lewy bodies 
(Choi et al., 2012; Mehlen et al., 1996; Mehlen et al., 1996a; Shimura et al., 2004; Zourlidou et 
al., 2004). p38 can also be ubiquitinated by the E3 ubiquitin ligase parkin and degraded (Ko et 
al., 2005). Parkin is downregulated in PD which causes an increase in p38. 
 
2.1.6 Cell Death 
Cytosolic ROS can directly cause apoptosis by activating the caspase cascade (Choi et al., 2004; 
Ko et al., 2005), and mitochondrial ROS can indirectly activate the caspase cascade by opening 
the PTP of the mitochondria and releasing cytochrome c (Moon et al., 2005), SMAC/DIABLO, 
and AIF. SMAC/DIABLO increases caspase activity by binding to IAP proteins, which prevent 
the IAP from binding to and inhibiting caspases 3 and 9. Cell death can also be triggered in a 
caspase-independent manner by DNA fragmentation and chromosome condensation initiated by 
Model 6: Cellular processes contributing to the death of SNPc neurons in PD 
the migration of the AIF from the mitochondria to the nucleus (Susin et al., 1999). Furthermore, 
hyperphosphorylated tau can create neurofibrillary tangles and Lewy bodies, inducing cell death. 
 
2.2 Modeled Pathways in AD 
An explanation of central pathways in the model, showing circumstances in which insulin 
signaling influences the pathology of AD. The system was modeled using the biochemical 
pathway visualization program CellDesigner. 
 
Model 7: Insulin signaling and inflammatory pathways in AD 
 2.2.1 Insulin Signaling and Inflammation 
Insulin signaling in Alzheimer’s disease (Model 7) begins when an insulin molecule binds to the 
insulin receptor, which activates the insulin receptor substrate and begins a signaling cascade. In 
addition to insulin resistance from inflammation, as seen in Parkinson’s disease, amyloid beta 
oligomers can interfere with insulin signaling by interacting with insulin receptors and 
preventing insulin from reaching the receptor (DiCarlo et al., 2010). Microglia and astrocytes 
play a major role in the inflammatory process in Alzheimer’s disease through the activation of 
NF-kB, a transcription factor that promotes the expression of inflammatory cytokines including 
IL-6, IL-1β, and TNFα (Hayashi et al., 1993). NF-kB also promotes the expression of the 
enzymes iNOS and COX2, which catalyze reactions that produce NO and O2-, respectively 
(Arias-Salvatierra et al., 2011; Chandel et al., 2000; Cogswell et al., 1994; Heyen et al., 2000; 
Kaltschmidt et al., 2002; Van Wagoner et al., 1999). These reactive molecules also contribute to 
inflammation (Glass et al., 2010; Mander et al., 2005). 
 
2.2.2 ROS and Mitochondrial Dysfunction 
NO created by iNOS during the inflammatory process (Model 8) is able to diffuse across cell 
membranes and react with O2- in the neuron, creating the highly toxic ROS ONOO- (Beckman, 
Crow, 1993). The O2- can also degrade into H2O2, and subsequently OH-, both of which are also 
harmful, or instead from H2O2 to water in the presence of glutathione (Evans et al., 2002). The 
primary source of O2- is the mitochondria, where it is produced in small amounts during normal 
respiratory functions. During mitochondrial dysfunction, especially in the respiratory complex I, 
larger amounts of O2- are formed (de la Monte et al., 2014). This oxidative stress in turn creates 
further dysfunction in complex I, which can then lead to mitochondrial membrane 
depolarization. When the mitochondrial membrane is compromised, the H+ ions can leak 
through, and the H+ gradient that drives ATP-synthase is weakened, causing ATP depletion. 
Without ATP, the cell has no way of transferring energy and will soon die.  (Atlante et al., 2008). 
Mitochondrial membrane depolarization can also be triggered by the truncation of the 
mitochondrial membrane protein BID by the proteins caspase 8 and calpain (Di Carlo et al., 
2010; Kelly et al., 2006; Snyder et al., 2009). 
 
 
2.2.3 Ca2+ Dysregulation 
Ca2+ is an important signaling molecule in neurons, but can be harmful at high concentrations. 
Ca2+ usually enters the cytosol from the extracellular environment (Model 9). Ca2+ is also 
sequestered in the endoplasmic reticulum. During endoplasmic reticulum stress, which can be 
Model 8: Reactive oxygen species synthesis and causes and consequences of mitochondrial 
dysfunction in AD 
triggered by events such as an accumulation of misfolded proteins, the Ca2+ stores can be 
released (Casley et al., 2009; Katayama et al., 2004). During Alzheimer’s disease conditions, Aβ 
oligomers can interact with the Ca2+ voltage-gated ion channels and NMDA receptors to 
dysregulate Ca2+ signaling (DeWachter et al., 2009; Mota et al., 2014; Nicholson et al., 2009; 
Snyder et al., 2005; Wang et al., 2005). Once Ca2+ levels in the cytosol become too high, the 
Ca2+ can activate the protein calpain, which can increase the accumulation of both Aβ oligomers 
and neurofibrillary tangles (Goñi-Oliver et al., 2007; Kelly et al., 2006). The Ca2+ can also enter 
the mitochondria, which it can activate NADPH oxidase, which promotes the formation of O2 
during the oxidation of NADPH to NADP+, contributing to mitochondrial dysfunction 
(Stutzmann, 2007). 
Model 9: Causes and consequences of abnormal Ca2+ signaling in AD cells 
 2.2.4 Neurofibrillary Tangles 
Neurofibrillary tangles are comprised primarily of hyperphosphorylated tau proteins, which 
usually function to stabilize the cytoskeletal microtubules (Model 10). When the tau are 
hyperphosphorylated, however, they release from the microtubules and aggregate into 
neurofibrillary tangles. Calpain, p38, and GSK-3β, which is inhibited by the insulin signaling 
kinase cascade, can all contribute to tau hyperphosphorylation (Johnson et al., 1989; Li et al., 
2003). Once the tau proteins are phosphorylated, inflammatory conditions create an environment 
suitable to aggregation (Liu et al., 2014). Phosphorylated insulin receptor substrate can also 
relocate from the nucleus to colocalize with neurofibrillary tangles. Aβ oligomers can activate 
Model 10: Neurofibrillary tangle production and triggers in AD 
the nuclear protein Jun, which then phosphorylates the insulin receptor substrate (Ma et al., 
2009). 
 
2.2.5 β-secretase and Aβ Oligomers 
APP expression is promoted by IL-1β signaling from the glia during inflammation (Model 11). 
Il-1β also increases the rate of APP cleavage into Aβ fragments, which is catalyzed by the 
enzyme β-secretase (Li et al., 2003). β-secretase expression is promoted by NF-kB in neurons 
during Alzheimer’s disease conditions, as well as by inflammation (Bourne et al., 2007; Heneka 
et al., 2005). Once it is created, it can then be activated by calpain after Ca2+ dysregulation 
(Goñi-Oliver et al., 2007). Aβ oligomerization is promoted by GSK-3β, which is inhibited by 
insulin signaling. Once the Aβ oligomers are created, however, they inhibit further insulin 
signaling (Di Carlo et al., 2010). Aβ oligomers have recently been identified as the toxic species 
of Aβ in Alzheimer’s disease instead of plaques. They contribute to further Ca2+ dysregulation 
Model 11: Production of activated beta secretase and consequent formation of amyloid beta 
oligomers and onset of their toxic effects in AD 
as previously discussed. Lysosome permeability occurs when the lysosomes attempt to degrade 
Aβ but become overwhelmed. This releases other toxic lysosomal content into the cytosol 
causing further stress to the cell (De Kimpe et al., 2013). 
 
2.2.6 p38 Phosphorylation and Cell Death 
The protein p38 plays multiple roles in initiating apoptotic processes in distressed cells. It can be 
inhibited by insulin signaling, but activated by inflammation via IL-1β as well as the ROS NO 
and O2- (Li et al., 2003). p38 blocks synaptic signaling by preventing the actions of the synaptic 
protein synaptophysin. It also acts to phosphorylated tau, contributing to the production of 
neurofibrillary tangles. It also converts procaspase 9 to caspase 9, which then joins the 
apoptosome and triggers apoptosis, as well as converts procaspase 8 to caspase 8, causing 
Model 12: Cellular processes contributing to p38 phosphorylation and neuronal death in AD 
mitochondrial stress (Di Carlo et al., 2008). Cell death can be caused by many of the processes 
controlled by p38, including ROS from mitochondrial dysfunction, neurofibrillary tangle 
buildup, and apoptosis (Liu et al., 2014; Mota et al., 2014). Endoplasmic reticulum stress from 
Ca2+ dysregulation and lysosome permeability from Aβ oligomer degradation attempts are also 
contributing factors (De Kimpe et al., 2013; Katayama et al., 2004). 
 
2.3 Biochemical Systems Theory 
The system was mathematized using BST to create a dynamic model in MATLAB of the species 
concentrations and reaction rates as they change over the course of the disease. For further 
information on the use of BST to model neurodegenerative disease systems using PLAS, see this 
lab’s previous work (Broome, Coleman, 2011; Sass et al., 2009; Yeager, Coleman, 2010).  
 
2.3.1 Initial Values 
Initial values are assigned to both independent and dependent variables. Independent variables 
are species that are not the products of any process or reaction in the system, whereas dependent  
variables are the product of at least one process or reaction. The values are assigned on a relative 
rather than absolute basis which allows for the estimation of unknown values. When available, 
values from the literature are taken into consideration and adapted to the relative scale. 
 
2.3.2 Flux Equations 
Flux equations, each of which is assigned a location in the matrix J, describe the relative reaction 
rates. Each flux equation takes into account the concentrations of the reactant species and a rate 
constant or rate equation. Every reaction or process in the model is assigned a flux equation. Flux 
equations take the following form: J(88) = X(258)*Xind(75). In this case, J(88) represents L-
DOPA synthesis, the 88th value in J. Xind(75) represents the independent variable tyrosine, and 
X(258) represents the rate ODE. Rate equations consist of a constant multiplied by the sum of all 
promoters and inhibitors, where promoters have positive concentration values and inhibitors 
have negative concentration values. In this case, X(258) = 0.0001*X(92), where X(92) represents 
the promoter phosphorylated tyrosine hydroxylase. In the event that a reaction or process does 
not include any promoters or inhibitors, a rate constant, specified as a value in the array k, is 
included instead. An example of an unmodified reaction is the equation for the formation of the 
IAP inhibition complex: J(96) = k(54)*Xind(82)*X(102), where k(54) is the rate constant, 
X(102) is cytosolic SMAC/DIABLO, and Xind(82) is IAP.  
 
2.3.3 Systems Equations 
Each dependent variable is assigned a systems equation, which describes the relative 
concentration of the species. Systems equations consist of the sum of all the flux equations in 
which the dependent variable is a reactant subtracted from the sum of all flux equations in which 
the dependent variable is a product. For example, X(93) = X(258)*Xind(75) – X(259)*X(93),  
where X(93) represents L-DOPA, X(258)*Xind(75) represents L-DOPA synthesis from tyrosine, 
and X(259)*X(93) represents dopamine synthesis from L-DOPA. 
 
2.3.4 Data Analysis 
This system exists in three states: a baseline state, a disease state, and a treatment state. In order 
to analyze the effects of neurodegeneration on the system, the baseline state is subtracted from 
the disease state so that any species with a positive value is elevated during the disease and any 
species with a negative value means the species is less present in neurodegeneration. The 
treatment state is compared to the baseline state in the same manner. Two treatment states, one in 
which the treatment is introduced at disease onset, and one in which treatment is introduced 
halfway through disease progression (t = 75), are created. This delay is a novel technique in the 
evaluation of treatments in neurodegeneration using BST, and provides significant insight into 
the efficacy of the treatment states. The delay is a more realistic simulation of the effects the 
treatments will have on the patient, as diagnosis and subsequent treatment at disease onset is 
unlikely to occur. The comparative disease state and two comparative treatment states are then 
Figure 1: Insulin Signaling in PD A comparison between a Parkinson disease model that 
initially includes insulin resistance and one that begins with normal insulin signaling. 
graphed together in order to assess the impact of the treatment strategy on the disease both in the 
best-case scenario and the more realistic scenario. 
 
3. PD Results 
3.1 Insulin Signaling and Inflammation 
3.1.1 Disease State 
Insulin signaling is impaired by decreasing the rate at which it binds to the insulin receptor. The 
relative concentration of the insulin receptor complex continues to decrease as the disease 
progresses. Normal insulin signaling also decreases compared to the baseline in response to the 
Figure 2: Inflammation in PD An increase in inflammation which is to some extent corrected 
by the treatment state. 
effects of PD (Fig.1). Inflammation increases in the PD state compared to the baseline state as a 
result of an increase in ROS, NF- κB signaling in the astrocytes and microglia, and cytokine 
expression (Fig. 2). 
 
3.1.2 Treatment State 
The lack of insulin signaling is partially corrected for by the inclusion of pioglitazone and 
sodium butyrate, which act as insulin sensitizers (Gao et al., 2009; Hu et al., 2013). Insulin 
signaling is fully recovered in the model when it is initially at normal levels, and is significantly 
recovered in the insulin resistant model as well during full treatment (Fig. 1). With a delayed 
initiation of treatment, insulin signaling in both the initially insulin resistant and initially insulin 
sensitive models are partially corrected but continue on a downward trend. Treatments of vitamin 
D (Chang et al., 2004), NAC, and aspirin (Ambhore et al., 2014) correct inflammation. Vitamin 
D inhibits NOS from producing pro-inflammatory NO in the glia. NAC inhibits NF- κB from 
entering the nucleus (Oka et al., 2000), thereby reducing expression of inflammatory cytokines. 
NAC also acts as a COX2 inhibitor, reducing the production of prostaglandins. Aspirin 
acetylates COX2, inhibiting its function as a promoter of prostaglandin synthesis. The decrease 
in cytokine, NO, and prostaglandin concentrations accordingly decrease inflammation, although 
inflammation is still largely present (Fig. 2). The full treatment state was similar to the delayed 
state in the prevention of inflammation.  
 
 
 
 
 3.2 Dopamine 
3.2.1 Disease State 
Dopamine levels are manipulated in the disease state by decreasing the concentration of VMAT 
transporters that allow the dopamine to be sequestered into vesicles. Extracellular dopamine 
concentrations are reduced to account for the degeneration of nearby dopaminergic neurons from 
PD, thereby reducing intercellular dopamine signaling. Dopamine degradation rates are increased 
in the disease state. Cytosolic dopamine levels actually increase in the PD model (Fig. 3); 
however, vesicle dopamine is decreased (Fig. 4). Cytosolic dopamine is undesirable in the cell 
Figure 3: Cytosolic Dopamine in PD Increased levels of cytosolic dopamine levels which are 
eventually fully rectified in the treatment state. 
because it is vulnerable to degradation into ROS. Vesicle dopamine is the preferred form because 
it is protected from degradation and is available for signaling at the synapse.  
 
 
3.2.2 Treatment State 
Treatments for dopamine imbalances in the PD neuron include vitamin D (Puchacz et al., 1996) 
and edaravone (Xiong et al., 2011). These two treatments complement each other because 
vitamin D increases cytosolic dopamine levels by increasing expression of tyrosine hydroxylase, 
which is important in dopamine synthesis, while edaravone promotes VMAT expression, 
Figure 4: Vesicle Dopamine in PD The decrease in cytosolic dopamine levels in the disease 
state is prevented in the treatment state, and the vesicle concentration becomes more constant. 
increasing the ability of dopamine to be transported to the vesicles. The treatment state initially 
follows the disease state progression with a sharp increase in cytosolic dopamine levels and 
corresponding decrease in dopamine vesicle concentration, but then corrects to normal cytosolic 
dopamine levels (Fig. 3). Full treatment returns to normal levels much more quickly than delayed 
treatment does, and delayed treatment reaches the same maximum concentration difference as 
the disease state before declining. Only a slight decrease from baseline in vesicle dopamine 
concentration is observed with full treatment (Fig. 4). Delayed treatment allows for a much 
larger gap from the baseline that is never recovered within the scope of the model. 
 
Figure 5: Reactive Oxygen Species in PD The level of reactive oxygen species is much lower 
in the treatment state than the disease state. 
3.3 ROS and RNS 
3.3.1 Disease State 
Mitochondrial dysfunction, dopamine metabolism rate, ROS production rates, and RNS 
production rates are increased in the disease state while antioxidant concentrations are decreased 
to trigger ROS and RNS accumulation. The ROS and RNS portrayed in Figure 5 consist of the 
sums of the levels of cytosolic O2-, H2O2, OH-, ONOO-, NO, and mitochondrial O2- in the 
neuron, as well as extracellular NO.  
 
3.3.2 Treatment State 
Antioxidant treatments included in the model are vitamin D, edaravone, and NAC (Samuni et al., 
2013). Vitamin D can help to decrease cytosolic O2- concentrations, and prevent Ca
2+ influx into 
the cell. Ca2+ buildup in the mitochondria can cause excess O2- production (Gandhi et al., 2009). 
Edaravone prevents mitochondrial DNA damage, reducing mitochondrial dysfunction (Xiong et 
al., 2011). NAC acts as an antioxidant in several ways. It is a precursor to glutathione, which is 
important in neutralizing H2O2. It can also react with ONOO- to degrade it into NO2- and OH-, 
and then react with those two species to form HNO2 and water. Full treatment greatly reduced  
ROS and RNS presence in the neuron (Fig. 5). Delayed treatment originally follows the course 
of the disease state, but then begins to approach the full treatment state. 
 
3.4 Tau Phosphorylation, Neurofibrillary Tangles, and Lewy Bodies 
3.4.1 Disease State 
Tau phosphorylation is triggered by increasing activated GSK-3β concentrations by decreasing 
insulin signaling, indirectly triggering p38 phosphorylation, and increasing α-synuclein 
aggregations, which interact with tau and create toxic accumulations of the two proteins (Lei et 
al., 2010). Hyperphosphorylated tau in the disease state increases sharply compared to the 
baseline state (Fig. 6). Neurofibrillary tangles are a consequence of tau hyperphosphorylation 
and increase accordingly (Fig. 7). Lewy bodies are the result of aggregated α-synuclein, 
hyperphosphorylated tau, and other misfolded proteins, and increase in concentration as these 
species become more numerous (Fig. 8). 
 
 
 
Figure 6: Phosphorylated Tau in PD Tau Phosphorylation is elevated in Parkinson’s disease, 
but is slowed in the treatment state. 
3.4.2 Treatment State 
Treatments included in the model that affect tau phosphorylation, neurofibrillary tangles, and 
Lewy bodies are lithium (Petit-Paitel et al., 2009), edaravone (Zhou et al., 2013), and sodium 
butyrate (Taylor et al., 2013). Lithium promotes GSK-3β phosphorylation, which prevents it 
from phosphorylating tau. Edaravone also inhibits tau phosphorylation. Sodium butyrate triggers 
the expression of MKP-1, which prevents tau phosphorylation by inhibiting p38 activation. 
Phosphorylated tau is considerably diminished in the treatment state, but is still present (Fig. 6). 
Neurofibrillary tangles (Fig. 7) and Lewy bodies (Fig. 8) decline at a greater rate. In these three 
cases, a delayed treatment does cause a decrease in species concentration, but still continues the 
Figure 7: Neurofibrillary Tangles in PD Neurofibrillary tangles are increasingly present in 
the disease state, but are present at a lower level in the treatment state. 
upward trend characteristic of the disease state. Delayed treatment slows the accumulation of 
these species but does not prevent it. 
  
 
3.5 p38 Phosphorylation 
3.5.1 Disease State 
 Decreasing the rate of insulin signaling, increasing the concentrations of ROS, and increasing 
the presence of prostaglandin J2 from the baseline state increases the activation of p38 in the 
disease state (Fig. 9). A decrease in the availability of parkin as an E3 ubiquitin ligase in the p38 
degradation pathway is also a contributing factor to the excess p38 phosphorylation. As a result 
Figure 8: Lewy Bodies in PD Lewy body increase in Parkinson’s disease is lessened in the 
treatment state. 
of p38 phosphorylation, mitochondrial dysfunction, apoptosis, tau phosphorylation, dopamine 
synthesis, and Hsp27 activation also increase. 
 
3.5.2 Treatment State 
The full treatment state reduces p38 concentrations past the baseline state (Fig. 9). Activation of 
MKP-1 through sodium butyrate treatment inhibits p38 phosphorylation (Taylor et al., 2013). 
Sodium butyrate increases expression of the DUSP1 gene, increasing the expression of MKP-1. 
This phosphatase is responsible for dephosphorylating p38, rendering it inactive. The reduction 
in ROS levels also contributed to the decline of the p38 concentration, as they are less available 
Figure 9: Phosphorylated p38 in PD The disease state includes increased phosphorylation of 
p38, which is attenuated in the treatment state. 
to promote the phosphorylation. Delayed treatment failed to produce similar results. Instead, it 
predicted an increase in phosphorylated p38 compared to the baseline state, but still produced a 
positive impact by remaining at a lower concentration than in the disease state. 
 
3.6 Cell Death 
3.6.1 Disease State 
Cell death can be triggered by apoptosome formation following activation of the caspase cascade 
by ROS in the cytosol, or by mitochondrial dysfunction and release of cytochrome c. Both 
cytosolic and mitochondrial ROS are elevated in the disease state. Lewy bodies and 
Figure 10: Cell Death in PD The treatment state corrects for some of the cell death caused by 
pathways influenced by insulin signaling in Parkinson’s disease. 
neurofibrillary tangles can also cause cell death. Finally, DNA fragmentation and chromosome 
condensation caused by AIF presence in the nucleus can lead to apoptosis. AIF is released along 
with cytochrome c as the PTP opens on the mitochondrial membrane. These factors all 
contribute to the increased probability of apoptosis seen as the model progresses (Fig.10). 
 
3.6.2 Treatment State 
Apoptosis is prevented by several drugs including edaravone (Cheng et al., 2014; Xiong et al., 
2011), Sodium butyrate (Taylor et al., 2013), cyclosporin A, and nortriptyline (Lamarche et al., 
2012). Edaravone prevents apoptosis by inhibiting tau phosphorylation, promoting the 
expression of the mitochondrial protein Bcl-XL, and inhibiting the expression of the related Bax 
protein. The Bax protein binds to the truncated version of Bid and increases opening of the PTP. 
Bcl-XL can bind to the Bax/Bid complex to prevent this process. Sodium butyrate inhibits the 
apoptotic proteins Jun and p38 from being activated through its promotion of MKP-1 expression. 
Cyclosporin A and nortriptyline prevent the PTP from opening and releasing apoptotic factors 
such as cytochrome c, SMAC/DIABLO, and AIF. Cell death is successfully prevented if the 
treatment is presented at disease onset, but is still present, albeit in a diminished state, when the 
treatment is delayed. 
 
4. AD Results 
4.1 Insulin Signaling and Inflammation 
4.1.1 Disease State 
Insulin resistance (Fig. 11) was achieved by decreasing the rate at which insulin bound to its 
receptor and at which the receptor substrate was activated. The condition was further exacerbated 
in the disease state with the onset of inflammation and the presence of Aβ oligomers, which 
compete with insulin for receptor interactions. Inflammation (Fig. 12) is triggered in the glia by 
the presence of ROS and the release of NF-kB from its inhibitor, allowing it to enter the nucleus 
and begin its actions as a transcription factor for pro-inflammatory cytokines and enzymes that 
produce even more ROS.  
 
4.1.2 Treatment State 
Figure 11: Insulin Signaling in AD Progressive insulin signaling accompanying AD is 
attenuated with insulin sensitizing treatment 
Insulin sensitization (Fig. 11) is achieved in this model by the inclusion of pioglitazone and 
sodium butyrate, which increase interactions between insulin and its receptor (Gao et al., 2009; 
Heneka et al., 2005). Pioglitazone and sodium butyrate are successful in recovering normal 
insulin signaling in both a full treatment scenario and recover almost all signaling in the delayed 
treatment model, although because the signaling had already been further decreased, it acted 
more slowly than the full treatment. This model does not include a treatment for inflammation 
directly, and once NF-kB has been activated by ROS, the presence of antioxidants, which the 
model does include, will not necessarily stop inflammation triggered by the newly expressed pro-
Figure 12: Inflammation in AD Inflammatory processes in AD increase as the disease 
progresses 
inflammatory cytokines. The inflammation does decrease slightly from the reduction of ROS 
(Fig. 12). 
 
4.2 ROS and Mitochondrial Dysfunction 
4.2.1 Disease State 
The concentration of ROS in the model was determined by summing the concentrations of all 
ROS in the neuron, astrocyte, and microglia and include O2-, H2O2, OH-, NO, and ONOO-. In 
the disease model, the ROS steadily increase during the progression of the disease state (Fig. 13). 
ROS contribute to cell damage by reacting with lipids, proteins, and DNA and altering or 
Figure 13: Reactive Oxygen Species in AD O
2
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, OH-, and ONOO- in neurons, 
astrocytes, and microglia all increase with AD 
preventing their function. Mitochondria are especially vulnerable to ROS toxicity because 
respiration is a major source of ROS in the cell. Mitochondrial dysfunction data shown (Fig. 14) 
includes both complex I dysfunction and mitochondrial membrane depolarization, which both 
interfere with normal respiratory function and contribute to further production of ROS. In the 
model, mitochondrial dysfunction increases at an increasing rate over the course of AD. 
 
4.2.2 Treatment State 
The treatment strategy for mitochondrial dysfunction focused on preventing ROS buildup. The 
antioxidant curcumin was chosen for this model. Curcumin is a naturally occurring substance 
Figure 14: Mitochondrial Dysfunction in AD Complex I dysfunction and mitochondrial 
membrane depolarization can both be prevented by the neutralization of reactive oxygen 
species 
that is present in the spice turmeric, and is responsible for its characteristic yellow color. 
Curcumin is able to neutralize two ROS per molecule by donating H+ to the ROS, rendering 
them less reactive (Barzegar 2012). The curcumin is able to reduce the amounts of ROS in the 
system, but not completely erase their presence (Fig. 13). Interestingly, delayed treatment is able 
to quickly reduce ROS concentrations to full treatment levels. This does not, however, transfer to 
mitochondrial dysfunction (Fig. 14). Almost all mitochondrial dysfunction is able to be 
attenuated by the presence of an antioxidant if it is administered at the onset of the functional 
Figure 15: Ca
2+
 Dysregulation in AD  Ca
2+
 increases in toxic amounts in Alzheimer’s disease, 
which can be prevented by inhibition of Ca
2+
 entering the cell from the extracellular 
environment 
deterioration. If it is administered after some dysfunction has already occurred, however, it can 
delay but not prevent further respiratory inhibition. 
 
4.3 Ca2+ Dysregulation 
4.3.1 Disease State 
Ca2+ influx can occur from two sources in the model: entry into the cell from ion channels and 
release of Ca2+ stores in the endoplasmic reticulum in response to stressors. Both of these 
processes are activated in AD with the result that the intracellular Ca2+ concentration increases 
during the disease state (Fig. 15), leading to abnormal Ca2+ signaling that contributes further to 
disease progression. 
 
4.3.1 Treatment State 
The treatment state focused on preventing Ca2+ influx from ion channels, not preventing 
endoplasmic reticulum Ca2+ release. The channel blocker MRS2481 is included in the model to 
this effect (Diaz et al., 2009). If added before any abnormal Ca2+ signaling, the inhibitor 
effectively prevents an overabundance of Ca2+ in the cytosol (Fig. 15). If Ca2+ has already started 
to accumulate, however, the treatment can only partially block further dysregulation. This 
additional Ca2+ may derive from the endoplasmic reticulum, as too much cytosolic Ca2+ can 
cause the endoplasmic reticulum to release its Ca2+ stores, further exacerbating the aberrant 
signaling (Casley et al., 2009). 
 4.4 Neurofibrillary Tangles 
4.4.1 Disease State 
Neurofibrillary tangles are increased in the Ad model compared to the baseline in several ways. 
The increased insulin resistance prevents a kinase cascade that blocks GSK-3β, which can 
phosphorylate tau. Additionally, Ca2+ increases activate calpain to further increase tau 
hyperphosphorylation. Finally, ROS can cause inflammation and p38 activation, both of which 
can contribute to tau hyperphosphorylation. These hyperphosphorylated tau are then able to 
Figure 16: Neurofibrillary Tangles in AD Neurofibrillary tangles increase during AD, but can 
be prevented primarily by inhibiting tau phosphorylation 
accumulate in neurofibrillary tangles, which are present in increasing amounts in the AD model 
(Fig. 16). 
 
4.4.2 Treatment State 
The treatment state includes several methods of reducing neurofibrillary tangle production. 
Curcumin as an antioxidant prevents some inflammation and p38 phosphorylation. Pioglitazone 
can inhibit GSK-3β activity by increasing insulin signaling. MRS2481 reduces calpain activation 
by reducing Ca2+ signaling. With the final addition of a direct GSK-3β inhibitor, lithium chloride 
(Noble et al., 2005), neurofibrillary tangles are dramatically decreased in the full treatment 
Figure 17: Beta Secretase in AD Increases in beta secretase concentrations are corrected in the 
treatment state 
model (Fig. 16). In the delayed treatment state, the neurofibrillary tangle formation process can 
only be partially corrected. 
 
4.5 β-secretase and Aβ Oligomers 
4.5.1 Disease State 
β-secretase is increased in the model (Fig. 17) through the increase in inflammation and 
indirectly by Ca2+ signaling from an increase in calpain. Accordingly, Aβ oligomers are 
increased (Fig. 18) through the increased production of Aβ from β-secretase increase, amplified 
Figure 18: Amyloid Beta Oligomers in AD Amyloid beta oligomers are greatly reduced in the 
treatment state compared to the disease state 
APP expression from glial IL-1β signaling as a result of inflammatory signaling, and greater 
GSK-3β activity from a lack of insulin signaling.  
 
4.5.2 Treatment State 
β-secretase is treated in the model through pioglitazone, which acts as a β–secretase inhibitor as 
well as an insulin sensitizer (Heneka et al., 2005). This treatment decreases β–secretase to near 
normal levels after an initial rise in concentration in the full treatment state (Fig. 17), and 
provides some inhibitory behavior, although to a lesser extent, in the delayed treatment model. 
Aβ oligomers sharply decrease in the full treatment state (Fig. 18). This is a result of a lack of Aβ 
Figure 19: p38 Phosphorylation in AD p38 is increasingly phosphorylated as AD progresses, 
but can be inhibited in the treatment state 
availability because of β-secretase scarcity, as well as inflammation decreases from curcumin’s 
antioxidant properties and recovered insulin signaling from pioglitazone sensitization. Curcumin 
also more directly inhibits Aβ aggregation (Ganugapati et al., 2015) by interacting with the 
active site of the APP. In the delayed treatment state, the oligomers also decrease below disease 
levels, but not to the extent of the full treatment. 
 
4.6 Phosphorylated p38 and Cell Death 
4.6.1 Disease State 
Figure 20: Cell Death in AD Cell death increases throughout disease progression, but is 
somewhat attenuated in the treatment state. 
p38 increases decidedly as the disease state advances (Fig. 19). This is a result of an increased 
number of ROS and inflammation accompanied by a decrease in insulin signaling. p83 activation 
triggers cell death in several ways, contributing to the increase in degeneration in the disease 
state (Fig. 20). Endoplasmic reticulum stress from abnormal cytosolic Ca2+ accumulation, 
lysosome permeability, and ROS more directly also contribute to the increasing likelihood that a 
neuron will die.  
 
4.6.2 Treatment State 
While p38 activation initially increases even during the full treatment state, it begins decreasing 
about halfway through the model (Fig. 19). The delayed treatment state also includes a decrease 
in p38 phosphorylation, but to a lesser extent. Curcumin as an antioxidant and pioglitazone as an 
insulin sensitizer help to prevent p38 activation, and an additional p38 inhibitor, sodium butyrate, 
is also included in the model (Taylor et al., 2013). Cell death is affected by every process 
previously discussed, and therefore every treatment included in the model works to ultimately 
prevent degeneration. This effort is somewhat successful, as the full treatment state decreases 
cell death, and improves slightly in efficacy as the model progresses (Fig. 20). The delayed 
treatment, however, is much less effective.  
 
5. Discussion 
5.1 PD 
5.1.1 Disease State 
The disease state model mimics the current understanding of PD in that it shows increases in 
inflammation, apoptotic factors, ROS and RNS, abnormal dopamine concentrations, and elevated 
levels of phosphorylated tau, neurofibrillary tangles, and Lewy bodies, which are characteristic 
of PD. These factors are only a fraction of the numerous of processes that typify PD, which also 
include but are not limited to the misfolding of α-synuclein, gene mutations, endoplasmic 
reticulum stress, and ubiquitin proteasome system malfunction, which are not fully explored in 
this model. The disease state modeled here is exacerbated by a loss of insulin signaling, usually 
caused by an excess of fats and sugars in the diet and a major factor in the development of 
T2DM.The model also suggests that dopaminergic neuronal insulin signaling is highly impaired 
in PD. This is likely caused by PD effects such as chronic inflammation and oxidative stress, 
which are common causes of insulin resistance in T2DM patients (Evans et al., 2002). 
 
5.1.2 Treatment State 
The model suggests a variety of treatment options to ameliorate both causes and symptoms of 
PD. Vitamin D, Li, aspirin, NAC, edaravone, pioglitazone, Sodium butyrate, cyclosporin A, and 
nortriptyline are the treatments included in the version of the model presented in this paper. 
Vitamin D acts as a ROS scavenger as well as decreasing inflammation. Lithium is a GSK 3β 
inhibitor. It is currently used as a treatment for bipolar disorder, but is being researched as a 
treatment for PD. Aspirin, a common, over-the-counter pain medication, is a NSAID and inhibits 
the inflammatory cytokine COX2. NAC acts as both an anti-inflammatory and antioxidant 
compound by inhibiting NF-κB, increasing glutathione concentrations, and reacting to neutralize 
ROS and RNS (Model 13). NAC is currently used as a treatment for a variety of psychiatric 
conditions including schizophrenia, obsessive-compulsive disorder, and addiction (Dean et al., 
2011). Edaravone protects against mitochondrial damage and tau phosphorylation, while 
promoting dopamine entry into vesicles. It is currently being investigated as a PD medication, as 
well as being involved in ongoing clinical trials to evaluate its potential as a treatment for ALS, 
another neurodegenerative disease. Pioglitazone is a known insulin sensitizer and is used in the 
treatment of T2DM. Sodium butyrate prevents apoptosis by inhibiting the activation of pro-
apoptotic proteins p38 and Jun. It also acts as an insulin sensitizer, and is currently being studied 
as a treatment for T2DM and the neurodegenerative condition Huntington’s disease. Cyclosporin 
A, an immunosuppressant, and nortriptyline, an antidepressant, both block apoptosis by 
preventing the PTP from opening.  
 
PD symptoms occur only after the disease progression is well under way. Treatment, therefore, is 
often delayed. This model includes one condition in which treatment is introduced at the onset of 
the disease, and one in which treatment is introduced halfway through the modeled disease 
progression. The differences between the scenarios highlight the importance of early detection of 
PD and, for the familial version of the disease, the introduction of possible preventative 
measures. The delayed treatment states for insulin resistance (Fig. 1), cell death (Fig. 10), p38 
phosphorylation (Fig. 9), Lewy bodies (Fig. 8), neurofibrillary tangles (Fig. 7), and tau  
Model 13: Example of treatment action—NAC as an antioxidant and NF-κB inhibitor 
in PD 
phosphorylation (Fig. 6) each resemble their disease state simulations more than their full 
treatment states. ROS (Fig. 5) and inflammation (Fig. 2) levels are partially corrected, but still 
high. Cytosolic dopamine (Fig. 3) levels eventually return to normal, and while vesicle dopamine 
(Fig. 4) levels are stabilized with treatment, the original concentration was not restored.  
 
5.2 AD 
5.2.1 Disease State 
The disease state accurately accounts for many of the pathological trends observed in AD brains, 
including increases in inflammation, cytosolic Ca2+, ROS and mitochondrial dysfunction, 
neurofibrillary tangles, Aβ oligomers, and cell death. Insulin resistance is connected to all of 
these changes and is a well characterized aspect of AD. Insulin signaling, or a lack thereof, 
affects the two main downstream components of AD, neurofibrillary tangles and Aβ oligomers, 
both of which are composed of pathologically modified proteins or peptide fragments. Both 
T2DM and T1DM effects, insulin receptor desensitization and a lack of insulin, are observed in 
AD conditions, further linking neurodegeneration to metabolic defects. 
 
5.2.2 Treatment State 
The approach to the AD treatment state was somewhat different than in the PD model. The PD 
model was more concerned with suggesting pathways to treat rather than specific compounds to 
treat them, although specific compounds were suggested. The AD model suggests five treatments 
instead of ten, representing a more realistic, although still complicated, drug cocktail. The AD 
treatments were chosen in many cases on their ability to affect multiple implicated pathways, 
allowing for a reduction in total treatments included. This approach minimizes the likelihood of 
severe side effects and drug interactions. These aspects were not investigated in the model, 
however, because the focus is on the pathways themselves, not specific treatments. If two of the 
treatments suggested happen to interact with each other, for instance, other compounds can be 
found that inhibit the same processes. 
 
This model included several treatments for AD that overlap with PD treatment suggestions. 
Sodium butyrate is able to sensitize the insulin receptor as well as prevent p38 activation, which 
are important processes that require intervention in both models. Lithium also acts more 
downstream of the insulin receptor to reduce tau hyperphosphorylation in both models. 
Pioglitazone was incorporated in the PD model as an insulin sensitizer only, but also acts as a β-
secretase inhibitor in the AD model. The molecule MRS2481 is a Ca2+ channel blocker and 
prevents an influx of Ca2+. Curcumin is a potent naturally occurring antioxidant molecule that is 
currently being investigated as a treatment for AD. Not only does it neutralize ROS, but it also 
prevents Aβ oligomerization by binding to the Aβ active site. Taken together, these treatments 
all contribute to the rectification of the multiple biochemical pathways affected by insulin 
resistance in AD. 
 
5.3 MATLAB 
This paper introduces a new protocol for coding neurodegenerative systems using MATLAB 
instead of PLAS. Unlike PLAS, MATLAB is capable of analyzing all aspects of the quantitative 
model, from solving the ODEs to preparing graphs. PLAS requires the use of separate programs 
such as Microsoft Excel for any data analysis and visualization required after the ODEs are 
solved. MATLAB is also able to take into account multiple qualitative outcome possibilities for 
a single species. In other words, MATLAB is able to recognize a condition, such as a species 
reaching a threshold concentration, and substitute the original equation with an alternate one 
leading to a qualitatively different outcome once the species reaches the threshold. Another 
advantage of MATLAB is the ability to order the solutions to the equations so that the species 
most sensitive to the change are immediately apparent. Finally, MATLAB can introduce new 
events, such as introducing or altering treatment dosages, at any time during the simulation. 
PLAS is only able to use the initial values given at the onset of the simulation. Overall, 
MATLAB is the more flexible and efficient analytical tool. 
 
6. Conclusion 
The two models described in this paper explore the reciprocal intensification of PD and insulin 
resistance and AD and insulin resistance through a mathematical lens. They provide a quick, 
cost-effective means of evaluating possible neurodegenerative disease treatment options for 
patients who also exhibit insulin resistance, and suggests mechanisms for the interactions 
between the conditions.  The PD model emphasizes dopaminergic neuron deterioration through 
ROS production via dysfunctional mitochondria and dopamine metabolism as well as Lewy body 
and neurofibrillary tangle production through hyperphosphorylated tau accumulation. The model 
also simulates the reduction in insulin signaling that occurs as a result of the chronic 
inflammation and ROS production that can accompany PD. Insulin signaling is partially lost 
even when it is not initially impaired. The AD model focuses on insulin signaling impairment 
through inflammatory processes, including ROS production and accompanying mitochondrial 
production, as well as Ca2+ dysregulation, the characteristic AD pathological components 
neurofibrillary tangles and Aβ oligomers, and lastly p38 phosphorylation and cell death. . 
Finally, the models evaluates the neuroprotective ability of a variety of treatments, both 
experimental and currently available to treat PD, AD, or T2DM. The models predict that a 
combined approach, initiated as early as possible and targeting a wide range of pathways, is the 
most effective.  
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